Skip to main content
. 2016 Nov 24;5:34–48. doi: 10.1016/j.conctc.2016.11.006

Table 4.

Simulation results: log-logistic dose-toxicity: Loge(DLT rate/(1−DLT rate)) = −16.8485 + 2.66078*loge(dose).

Design % of times that dose level 3 is selected as the MTD % of times that doses below the MTD (dose levels 1 and 2) are selected as the MTD % of times that doses above the MTD (dose levels 4 and above) are selected as the MTD Average number of dose levels examined Std of dose levels examined Max dose levels examined Median dose levels examined Average number of patients per trial Median number of patients per trial Median number of DLTs per trial Average sample size at MTD Average % of pts dosed at MTD Average % of pts under- dosed Average % of pts over- dosed
3 + 3a 49.45 (50.55) 31.66 (35.95) 18.72 (13.38) 3.8 0.8 7 4 14.2 (16.73) 15 (15) 3 (3) 4.00 (5.18) 28.72 (31.16) 48.61 (47.44) 22.67 (21.4)
2 + 4a 45.8 (50.89) 24.48 (33.94) 29.6 (15.05) 4.1 0.87 8 4 11.89 (16.29) 12 (16) 3 (3) 3.16 (5.19) 27.49 (32.71) 40.05 (37.8) 32.46 (29.49)
4 + 4 aa 56.73 (57.76) 20.26 (20.69) 23.01 (21.54) 4 0.7 6 4 21.96 (24.23) 20 (24) 5 (5) 6.18 (7.4) 29.09 (31.3) 42.78 (41.49) 28.13 (27.21)
5 + 5 aa 58.07 (58.09) 31.38 (33.18) 10.54 (8.71) 3.8 0.65 6 4 25.54 (28.43) 25 (30) 4 (5) 7.96 (9.37) 31.95 (33.38) 46.85 (46.63) 21.21 (19.99)
3 + 3+3 53.96 22.43 23.56 4 0.74 7 4 15.89 15 3 4.55 28.9 44.54 26.56
Simple accelerated titration 36.32 15.67 47.95 4.5 1.05 9 4 8.11 7 2 1.87 22.93 29.81 47.25
mTPI 63.15 22.45 14.35 7 7 7 24 (max) 24 (max) 10.0 41.67 40.49 17.85
TEQR 57 32 8 7 7 7 22.71 24 8.6 37.78 46.98 15.24
BOIN 59.2 28 12.7 7 7 7 24 (max) 24 (max) 3.7 (mean) 8.9 37.08 50 12.92
CRM 74 18 8 7 7 7 24 (max) 24 (max) 4.0 (mean) 10.1 41.92 43.42 14.67
EWOC 57.1 9.7 33.2 7 7 7 24 (max) 24 (max) 11.4 47.32 22.92 29.76

The bold highlighting shows the designs predicted by simulations to pick the MTD most accurately, to enroll the largest and smallest number of patients, to dose the maximum percentage of patients at the MTD, to under-dose the maximum percentage of patients, and to over-dose the maximum percentage of patients. Note also that the sum of columns 2 to 4 may add up to <100% because the remaining small percentage of times, no dose level is selected as the MTD.

a

The numbers shown in brackets are for a corresponding design that also allows dose de-escalation.